2021
Feuerstadt P, Boules M, Stong L, Dahdal DN, Sacks NC , Lang K, Nelson WW. 2021. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis. SAGE Open Med 9:2050312120986733.
View Abstract
Topics: Epidemiology , Health Economics and Outcomes Research (HEOR)
Hackshaw A, Cohen SS, Reichert H , Kansal AR, Chung KC, Ofman JJ. 2021. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Brit J Cancer 125(10):1432-1442; doi: 10.1038/s41416-021-01498-4 .
View Abstract
Topics: Cancer , Epidemiology
McGrath LJ, Nielson C, Saul B, Breskin A, Yu Y, Nicolaisen SK, … Kelsh M , et al. 2021. Lessons learned using real-world data to emulate randomized trials: A case study of treatment effectiveness for newly diagnosed immune thrombocytopenia. Clin Pharmacol Ther 110(6):1570–1578. doi: 10.1002/cpt.2399.
View Abstract
Topics: Epidemiology
Gage SM, Reichert H . 2021. Determining the incidence of needle-related complications in hemodialysis access: We need a better system. J Vascular Access 22(4)521-532; doi: 10.1177/1129729820946917 .
View Abstract
Topics: Epidemiology
Vágó EK, Nicholson G, Horváth-Puhó E. Hooda N , Fryzek JP, Su J. 2021. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. Curr Med Res Opin 37(10):1829-1835; doi: 10.1080/03007995.2021.1960494 .
View Abstract
Topics: Epidemiology
Sacks NC , Healey BE, Cyr PL , Slocomb T, James E, Beggs AH, Graham RJ. 2021. Costs and health resource use in patients with X-linked myotubular myopathy: insights from U.S. commercial claims. J Manag Care Spec Pharm 27(8):1019–1026; doi: 10.18553/jmcp.2021.20501 .
View Abstract
Topics: Epidemiology , Health Economics and Outcomes Research (HEOR)
Dean R, Jensen IS, Cyr PL , Miller B, Maru B, Sproule DM, Feltner DE, et al. 2021. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Pol 9(1):1889841; doi: 10.1080/20016689.2021.1889841 .
Topics: Health Economics and Outcomes Research (HEOR)
Nielson CM, Bylsma LC , Fryzek JP, Saad HA, Crawford J. 2021. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: A systematic review and meta-analysis. The Oncologist 26(9):e1609–e1618; doi: 10.1002/onco.13822 .
View Abstract
Topics: Epidemiology , Systematic Review
Rehorn M, Sacks NC , Emden MR, Healey B, Preib MT, Cyr PL , Pokorney SD. 2021. Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. J Cardiovasc Electrophysiol 32(8):2199-2206; doi: 10.1111/jce.15109 .
View Abstract
Topics: Epidemiology
Chew D, Sacks NC , Emden MR, Preib MT, Cyr PL , Wood D, Pokorney SD. 2021. Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States. Am Heart J 233(March):132–140; doi: 10.1016/j.ahj.2020.12.012 .
View Abstract
A Division of